Clinical Trial Update: Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours [Phase 3]

View source ↗

Summary

Phase 3 trial of lanreotide Autogel in non-functioning gastroenteropancreatic neuroendocrine tumors has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Lanreotide Autogel (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Endocrine Tumors | Phase 3 | Status: COMPLETED | Results posted: 2015-02-18